This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
This useful book is now in its third edition. It has been revised from previous editions by the larger and expanded therapeutic claims committee of the International Federation of Multiple Sclerosis (MS) Societies. This is composed of several well-known MS clinician-investigators, drawn from a worldwide constituency, and the information in this paperback represents their consensus. Although the committee might profit from including a clinical trial methodologist who could provide a non-MS perspective, this volume continues the fine tradition established in the first edition. The historical section, which was such an interesting feature in the first edition, has been abridged, but what is left still provides a sobering perspective on the fads and fancies of the last decades of MS therapy.
The proper design of an MS clinical trial is reemphasized with the appropriate stress placed on, for example, blinding and randomizations. These serve as a good background for the evaluation
Ebers GC. Therapeutic Claims in Multiple Sclerosis. Arch Neurol. 1994;51(8):746–747. doi:10.1001/archneur.1994.00540200020006
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.